Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“Since only 30%–50% of colorectal cancers have KRAS mutations [4,18,21], there has been speculation that the detection of KRAS mutation may portend a worse prognosis.”
BackgroundHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095 · cited 1×
“addition, miRNA expression is often lost in cancer because they tend to be located in genomic regions that are frequently lost during cancer development [67].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 4×
“The reduced expression of let-7 in cancer tissues corresponds to significantly higher levels of KRAS mRNA [70].”
BackgroundInfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690 · cited 1×
“Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0637 · Cited by 2,354 · cited 1×
“In addition to the important mechanistic role of let-7 miRNA in post-transcriptional regulation of KRAS gene expression, decreased let-7 miRNA expression has been associated with worse patient outcomes in lung cancer [71] and may also affect radiosensitivity.”
BackgroundKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 2×
“Additionally, they noted in a retrospective analysis that patients with wild-type KRAS had better overall survival compared to patients harboring mutant KRAS [37].”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 3×
“Conversely, KRAS G13D mutation has also been associated with worse overall survival compared to patients with other KRAS mutations or wild-type KRAS [49,50].”
BackgroundMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114 · cited 1×
“Over 90% of pancreatic adenocarcinomas [1], 30%–50% of colorectal cancers [2–4], 55% of thyroid cancers [5], 35% of lung cancers [5], and 35% of rhabdomyosarcomas [6] harbor mutated RAS genes.”
BackgroundMaas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945 · cited 1×
“Furthermore, up to 25% of these patients may have complete eradication of their tumors or achieve a pathologic complete response (pCR) [58].”
BackgroundRAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“(NIH) [10].”
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultPrevalence of ras gene mutations in human colorectal cancers
Bos, J. L., Fearon, E. R., Hamilton, S. R., Vries, M. V., van Boom, J. H., van der Eb, A. J., & Vogelstein, B. (1987) · Nature · doi:10.1038/327293a0 · Cited by 1,860 · cited 1×
“A number of reports have investigated the significance of specific KRAS point mutations which typically involve codons 12, 13, 59 or 61 [12,13].”
BackgroundAmbros, V. (2001) · Cell · doi:10.1016/s0092-8674(01)00616-x · Cited by 1,697
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636 · cited 1×
“Given the small sample size, no definitive conclusions could be reached about prognosis [43,46].”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 2×
“Interestingly, BRAF mutations, which are predominantly mutually exclusive of mutant KRAS, have also been associated with resistance to anti-EGFR treatment in colorectal cancer [53,55].”
BackgroundThe Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379 · cited 1×
“Another approach to targeting oncogenic KRAS is synthetic lethality, a phenomenon in which a combination of two or more gene mutations leads to cell death, but a mutation in one of those genes alone does not compromise cell viability [80].”
BackgroundThe COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,267 · cited 1×
“In fact, KRAS mutations comprise 86% of all RAS mutations [8].”
BackgroundDetection of high incidence of K-ras oncogenes during human colon tumorigenesis
Forrester, K., Almoguera, C., Han, K., Grizzle, W. E., & Perucho, M. (1987) · Nature · doi:10.1038/327298a0 · Cited by 1,061 · cited 1×
“A number of reports have investigated the significance of specific KRAS point mutations which typically involve codons 12, 13, 59 or 61 [12,13].”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“identified several genes in the mitotic pathway that have synthetic lethal interactions with KRAS [81].”
BackgroundKirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827 · cited 1×
“Over 90% of pancreatic adenocarcinomas [1], 30%–50% of colorectal cancers [2–4], 55% of thyroid cancers [5], 35% of lung cancers [5], and 35% of rhabdomyosarcomas [6] harbor mutated RAS genes.”
BackgroundUnderstanding Ras: ‘it ain’t over ’til it’s over’
Shields, J. M., Pruitt, K., McFall, A., Shaub, A., & Der, C. J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01740-2 · Cited by 780 · cited 2×
“Once activated, ras leads to the downstream activation of a wide variety of effectors including serine/threonine kinases, GTPase-activating proteins (GAPs), phosphoinositide 3-kinase (PI3K), and GEFs [11].”
BackgroundBokemeyer, C., Bondarenko, I., Hartmann, J. T., de Braud, F., Schuch, G., Zubel, A., Celik, I., Schlichting, M., & Koralewski, P. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq632 · Cited by 775 · cited 1×
“Given the small sample size, no definitive conclusions could be reached about prognosis [43,46].”
BackgroundKirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748
De Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748 · cited 1×
“Conversely, KRAS G13D mutation has also been associated with worse overall survival compared to patients with other KRAS mutations or wild-type KRAS [49,50].”
Slaby, O., Svoboda, M., Fabian, P., Smerdova, T., Knoflickova, D., Bednarikova, M., Nenutil, R., & Vyzula, R. (2007) · Oncology · doi:10.1159/000113489 · Cited by 682 · cited 3×
“Some of the better understood miRNAs that play a role in cell proliferation in colorectal cancer are lethal-7 (let-7) and miR-143 [64,66,68,69].”
Backgroundlet-7 MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells
Akao, Y., Nakagawa, Y., & Naoe, T. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.903 · Cited by 619 · cited 2×
“recently showed that let-7 miRNA may have a suppressive effect on growth and proliferation in human colon cancer cells [73].”
BackgroundBiological properties of human c-Ha-ras1 genes mutated at codon 12
Seeburg, P. H., Colby, W. W., Capon, D. J., Goeddel, D. V., & Levinson, A. D. (1984) · Nature · doi:10.1038/312071a0 · Cited by 585
Role of miR-143 targeting KRAS in colorectal tumorigenesis
Chen, X., Guo, X., Zhang, H., Xiang, Y., Chen, J., Yin, Y., Cai, X., Wang, K., Wang, G., Ba, Y., et al. (2009) · Oncogene · doi:10.1038/onc.2008.474 · Cited by 549 · cited 4×
“The role of miR-143 as a tumor suppressor was demonstrated through the ability of miR-143 inhibition to increase KRAS protein levels and cell proliferation in vitro [77].”
BackgroundInfluentialRodenhuis, S., Slebos, R. J. C., Boot, A. J., Evers, S. G., Mooi, W. J., WAGENAAR, S. S., Bodegom, P. C. V., & Bos, J. L. (1988) · PubMed · Cited by 465
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429 · cited 1×
“Several retrospective studies have indicated that the mutation status of BRAF may also be predictive of response to anti-EGFR therapies in patients with metastatic colorectal cancer [49,53,54].”
BackgroundInhibition of Ras for Cancer Treatment: The Search Continues
Baines, A. T., Xu, D., & Der, C. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.121 · Cited by 382 · cited 2×
“Of the three known human RAS genes, KRAS is most frequently mutated in cancer [7].”
BackgroundFrequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377 · cited 2×
“Interestingly, BRAF mutations, which are predominantly mutually exclusive of mutant KRAS, have also been associated with resistance to anti-EGFR treatment in colorectal cancer [53,55].”
BackgroundTejpar, S., Celik, I., Schlichting, M., Sartorius, U., Bokemeyer, C., & Van Cutsem, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2592 · Cited by 353 · cited 1×
“However, they also noted that the addition of cetuximab to first-line chemotherapy may benefit patients with KRAS G13D mutation [51,52].”
BackgroundmiRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Yu, S., Lu, Z., Liu, C., Meng, Y., Ma, Y., Zhao, W., Liu, J., Yu, J., & Chen, J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4531 · Cited by 328 · cited 1×
“KRAS mutations may prove both predictive of treatment efficacy and prognostic for patient outcomes; however, effective and optimized KRAS silencing therapeutic strategies remain to be developed [61].”
BackgroundRole of anti-oncomirs miR-143 and -145 in human colorectal tumors
Akao, Y., Nakagawa, Y., Hirata, I., Iio, A., Itoh, T., Kojima, K., Nakashima, R., Kitade, Y., & Naoe, T. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.88 · Cited by 262 · cited 4×
“Some of the better understood miRNAs that play a role in cell proliferation in colorectal cancer are lethal-7 (let-7) and miR-143 [64,66,68,69].”
BackgroundInfluentialThe KRAS oncogene: Past, present, and future
Kranenburg, O. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.10.001 · Cited by 252 · cited 1×
“Over 90% of pancreatic adenocarcinomas [1], 30%–50% of colorectal cancers [2–4], 55% of thyroid cancers [5], 35% of lung cancers [5], and 35% of rhabdomyosarcomas [6] harbor mutated RAS genes.”
BackgroundPrognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., & Quirke, P. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90835-z · Cited by 245 · cited 1×
“Over 90% of pancreatic adenocarcinomas [1], 30%–50% of colorectal cancers [2–4], 55% of thyroid cancers [5], 35% of lung cancers [5], and 35% of rhabdomyosarcomas [6] harbor mutated RAS genes.”
BackgroundSantini, D., Loupakis, F., Vincenzi, B., Floriani, I., Stasi, I., Canestrari, E., Rulli, E., Maltese, P. E., Andreoni, F., Masi, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0181 · Cited by 234 · cited 1×
“also showed that KRAS C12V mutations were more frequently associated with hepatic metastasis [34].”
BackgroundLIN28B Promotes Colon Cancer Progression and Metastasis
King, C. E., Cuatrecasas, M., Castells, A., Sepulveda, A. R., Lee, J.-S., & Rustgi, A. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4637 · Cited by 224 · cited 2×
“also showed that LIN28B+ tumors, which have repressed let-7, have increased metastases and stem cell markers that can sustain cancerous growth [74].”
BackgroundFrequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.
Capella, G., Cronauer-Mitra, S., Pienado, M. A., & Perucho, M. (1991) · Environmental Health Perspectives · doi:10.1289/ehp.9193125 · Cited by 214 · cited 1×
“As shown in Table 1, point mutations in codon 12 are the most common KRAS mutation in colorectal cancer [14–17].”
BackgroundSurvival and acquired genetic alterations in colorectal cancer
Laurent-Puig, P., Olschwang, S., Delattre, O., Remvikos, Y., Asselain, B., Melot, T., Validire, P., Muleris, M., Girodet, J., & Salmon, R. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)70006-w · Cited by 208 · cited 1×
“Unfortunately, the reports have been contradictory on the prognostic value of KRAS mutations [15,22–30].”
BackgroundFinkelstein, S. D., Sayegh, R., Christensen, S., & Swalsky, P. A. (1993) · Cancer · doi:10.1002/1097-0142(19930615)71:12<3827::aid-cncr2820711207>3.0.co;2-n · Cited by 204 · cited 1×
“clarified in the RASCAL study the association of specific KRAS mutations with patient outcomes and tumor characteristics [17,22].”
BackgroundMutations in the KRAS2 oncogene during progressive stages of human colon carcinoma.
Burmer, G. C., & Loeb, L. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2403 · Cited by 199 · cited 1×
“As shown in Table 1, point mutations in codon 12 are the most common KRAS mutation in colorectal cancer [14–17].”
BackgroundBorralho, P. M., Kren, B. T., Castro, R. E., Moreira da Silva, I. B., Steer, C. J., & Rodrigues, C. M. P. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07383.x · Cited by 195 · cited 1×
“In addition to antagonizing cell survival, miR-143 has also been shown to increase chemosensitivity to 5-FU in vitro [79].”
BackgroundEarle, J. S. L., Luthra, R., Romans, A., Abraham, R., Ensor, J., Yao, H., & Hamilton, S. R. (2010) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090154 · Cited by 180 · cited 2×
“Some of the better understood miRNAs that play a role in cell proliferation in colorectal cancer are lethal-7 (let-7) and miR-143 [64,66,68,69].”
BackgroundNash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172 · cited 2×
“observed that both KRAS mutation and high KI-67 expression were associated with multiple liver metastases, shorter time interval to their detection; and with poor survival after colon resection [33].”
BackgroundStratton, M. R., Fisher, C., Gusterson, B. A., & Cooper, C. S. (1989) · PubMed · Cited by 168
GLUT-1 expression in ovarian carcinoma: Association with survival and response to chemotherapy
Cantuaria, G., Fagotti, A., Ferrandina, G., Magalhaes, A., Nadji, M., Angioli, R., Penalver, M., Mancuso, S., & Scambia, G. (2001) · Cancer · doi:10.1002/1097-0142(20010901)92:5<1144::aid-cncr1432>3.0.co;2-t · Cited by 166
Reichert, T. E., Scheuer, C., Day, R., Wagner, W., & Whiteside, T. L. (2001) · Cancer · doi:10.1002/1097-0142(20010601)91:11<2136::aid-cncr1242>3.0.co;2-q · Cited by 162
MicroRNA in colorectal cancer: from benchtop to bedside
Wu, W. K. K., Law, P. T. Y., Lee, C. W., Cho, C. H., Fan, D., Wu, K., Yu, J. Q., & Sung, J. J. �. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq243 · Cited by 144 · cited 4×
“Some of the better understood miRNAs that play a role in cell proliferation in colorectal cancer are lethal-7 (let-7) and miR-143 [64,66,68,69].”
BackgroundInfluentialKim, M.-J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J.-O., Bang, S.-M., Park, K. U., Kim, D.-W., Kang, S.-B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 140 · cited 1×
“Further, in a recent study of 143 Korean patients with metastatic or recurrent colorectal cancer, lung metastasis was more frequently the initial metastatic site in patients with the KRAS mutations [35].”
BackgroundSelf-citationHemming, A. W., Davis, N. L., Kluftinger, A., Robinson, B., Quenville, N. F., Liseman, B., & Lcriche, J. (1992) · Journal of Surgical Oncology · doi:10.1002/jso.2930510304 · Cited by 128 · cited 1×
“Similar to KRAS mutations, EGFR overexpression has also been linked to poor prognosis and increased risk of metastasis in colorectal cancer and, therefore, represents a promising therapeutic target [40,41].”
BackgroundKing, C. E., Wang, L., Winograd, R., Madison, B. B., Mongroo, P. S., Johnstone, C. N., & Rustgi, A. K. (2011) · Oncogene · doi:10.1038/onc.2011.131 · Cited by 126 · cited 1×
“In an analysis of human non-metastatic colon cancers, expression of an upstream repressor of let-7, LIN28B, was associated with poorer patient survival [74,75].”
BackgroundGraziano, F., Canestrari, E., Loupakis, F., Ruzzo, A., Galluccio, N., Santini, D., Rocchi, M., Vincenzi, B., Salvatore, L., Cremolini, C., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.9 · Cited by 122
Dix, B. R., Robbins, P., Soong, R., Jenner, D., House, A. K., & Iacopetta, B. J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590606 · Cited by 116 · cited 1×
“reported that KRAS mutation was not prognostic in their cohort when predicting short-term survival [27].”
BackgroundSadi, M. V., & Barrack, E. R. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2574::aid-cncr2820710823>3.0.co;2-1 · Cited by 115
Zlobec, I., Kovac, M., Erzberger, P., Molinari, F., Bihl, M. P., Rufle, A., Foerster, A., Frattini, M., Terracciano, L., Heinimann, K., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25265 · Cited by 108
Duldulao, M. P., Lee, W., Nelson, R. A., Li, W., Chen, Z., Kim, J., & Garcia-Aguilar, J. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2910-0 · Cited by 104
Self-citationOudejans, J. J., Slebos, R. J. C., Zoetmulder, F. A. N., Mooi, W. J., & Rodenhuis, S. (1991) · International Journal of Cancer · doi:10.1002/ijc.2910490613 · Cited by 100 · cited 2×
“As shown in Table 1, point mutations in codon 12 are the most common KRAS mutation in colorectal cancer [14–17].”
BackgroundPichler, M., Winter, E., Stotz, M., Eberhard, K., Samonigg, H., Lax, S., & Hoefler, G. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.175 · Cited by 90 · cited 2×
“Colorectal cancer patients with low levels of miR-143 expression had a significantly higher risk of having shorter cancer-specific survival and progression-free survival [78].”
BackgroundBosset, J.-F., Pavy, J. J., Hamers, H. P., Horiot, J.-C., Clavero-Fabri, M.-C., Rougier, P. R., Eschwège, F., & Schraub, S. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90012-5 · Cited by 81 · cited 1×
“therapy [56,57].”
Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon
Pricolo, V. E., Finkelstein, S. D., Wu, T., Keller, G., Bakker, A., Swalsky, P. A., & Bland, K. I. (1996) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)80071-3 · Cited by 78
K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis
Suchy, B., Zietz, C., & Rabes, H. M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520107 · Cited by 76 · cited 1×
“clarified in the RASCAL study the association of specific KRAS mutations with patient outcomes and tumor characteristics [17,22].”
BackgroundMutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.
Morrin, M., Kelly, M., Barrett, N., & Delaney, P. (1994) · Gut · doi:10.1136/gut.35.11.1627 · Cited by 73 · cited 1×
“Unfortunately, the reports have been contradictory on the prognostic value of KRAS mutations [15,22–30].”
BackgroundTanaka, M., Omura, K., Watanabe, Y., Oda, Y., & Nakanishi, I. (1994) · Journal of Surgical Oncology · doi:10.1002/jso.2930570115 · Cited by 64 · cited 1×
“reported that KRAS mutation was an independent factor associated with prognosis in a multivariate analysis [23], whereas Dix et al.”
BackgroundBengala, C., Bettelli, S. R., Bertolini, F., Sartori, G., Fontana, A., Malavasi, N., Depenni, R., Zironi, S., Giovane, C. D., Luppi, G., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605853 · Cited by 53 · cited 1×
“2%) [59].”
LIN28B confers radio-resistance through the posttranscriptional control of KRAS
Jeong, S., Wu, H., & Park, W. (2009) · Experimental & Molecular Medicine · doi:10.3858/emm.2009.41.12.097 · Cited by 51 · cited 1×
“reported that the overexpression of let-7 miRNA inhibited translation of KRAS and subsequently increased the sensitivity of cells to ionizing radiation [72].”
BackgroundThe prognostic value of KRAS mutations in patients with colorectal cancer
Inoue, Y., Saigusa, S., IWATA, T., Okugawa, Y., Toiyama, Y., Tanaka, K., Uchida, K., Mohri, Y., & Kusunoki, M. (2012) · Oncology Reports · doi:10.3892/or.2012.1974 · Cited by 31 · cited 1×
“Unfortunately, the reports have been contradictory on the prognostic value of KRAS mutations [15,22–30].”
BackgroundActivation of Ha- ras p21 by Substitution, Deletion, and Insertion Mutations
Chipperfield, R. G., Jones, S. S., Lo, K.-M., & Weinberg, R. A. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.1809 · Cited by 31
Recently Identified and Potential Targets for Colon Cancer Treatment
Lea, M. A. (2010) · Future Oncology · doi:10.2217/fon.10.53 · Cited by 22 · cited 1×
“In the search for novel strategies in the treatment of colon cancer, miRNAs have received attention for their role in controlling gene expression [65].”
BackgroundPosition Specificity of Ki-ras Oncogene Mutations during the Progression of Colorectal Carcinoma
Rochlitz, C. F., Heide, I., de Kant, E., Böhmer, R., Peter, F. J., Neuhaus, P., Huhn, D., & Herrmann, R. (2009) · Oncology · doi:10.1159/000227150 · Cited by 21 · cited 1×
“Unfortunately, the reports have been contradictory on the prognostic value of KRAS mutations [15,22–30].”
BackgroundReinacher‐Schick, A., Schulmann, K., Modest, D. P., Bruns, N., Graeven, U., Jaworska, M., Greil, R., Porschen, R., Arnold, D., Schmiegel, W., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-349 · Cited by 15 · cited 1×
“chemotherapy [31].”
Troungos, C., Valavanis, C., Kapranos, N., & Kittas, C. N. (1997) · PubMed · Cited by 12
Tejpar, S., Bokemeyer, C., Celik, I., Schlichting, M., Heeger, S., & Cutsem, E. V. (2011) · Annals of Oncology · Cited by 3
Duldulao, M. P., Lee, W., Chen, Z., Li, W., Nelson, R. A., Kim, J., & García‐Aguilar, J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.4_suppl.453 · Cited by 1
Self-citation
Research works printed but not linked: 3
- Louvet, 2001, Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma, Cancer, 91, 2033, 10.1002/1097-0142(20010601)91:11<2033::aid-cncr1229>3.0.co;2-j · DOI · Paper page
- Goldstein, 2001, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system, Cancer, 92, 1331, 10.1002/1097-0142(20010901)92:5<1331::aid-cncr1455>3.0.co;2-m · DOI · Paper page
- Mayer, 1993, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer, Cancer, 71, 2454, 10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2 · DOI · Paper page
Cited by
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
“Anemia 0 (0) 1 (20) 0 (0) 0 (0) 6 (5) 5 (4) 0 (0) 3 (27) 15 (11)”
Self-citationBedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K., & Lim, C. T. (2018) · Lab on a Chip · doi:10.1039/c8lc00684a · Cited by 259
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 242
“KRAS mutations contribute to unregulated cell growth, ultimately leading to the expansion of tumour cell growth [85,86].”
Background
Metadata
- Authors
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J.
- Affiliations
- City Of Hope National Medical Center (US)
- University of Southern California (US)
- Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 11597, USA
- Corresponding author
- Arrington, Amanda K.
- Kim, Joseph
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-25
- Volume
- 13
- Issue
- 10
- Pages
- 12153-12168
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3497263
- OpenAlex
- W1991898744
- Cited by
- 244
- References
- 86
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 16 · 2021: 28 · 2020: 29 · 2019: 22 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 15 · 2014: 20 · 2013: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer, prognostic factors, predictive biomarkers, ras gene family, treatment resistance, tumor aggressiveness, survival
- MeSH terms
- Humans, Polymorphism, Genetic, Prognosis, Colorectal Neoplasms, ras Proteins, MicroRNAs, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


